Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 10/20 | 0.79 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ACP1 | P24666 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2664673 | 0.90 | GCK (0.74) | GCKFFAR2KCNH2POLBCYP1A2 | |
| SCHEMBL2645678 | 0.88 | GCK (0.81) | GCKFFAR2KCNH2SMN1; SMN2LMNA | |
| Ro-281675 SCHEMBL2646000 | 0.88 | GCK (1.00) | GCKFFAR2KCNH2 | |
| Ro-281675 SCHEMBL2645615 | 0.88 | GCK (1.00) | GCKFFAR2KCNH2 | |
| Ro-281675 SCHEMBL7089685 | 0.88 | GCK (1.00) | GCKFFAR2KCNH2 | |
| SCHEMBL2647740 | 0.88 | GCK (0.71) | GCKFFAR2KCNH2CYP1A2CYP3A4 | |
| SCHEMBL2647924 | 0.88 | GCK (0.71) | GCKFFAR2KCNH2CYP1A2CYP3A4 | |
| SCHEMBL3442050 | 0.87 | GCK (0.71) | GCKFFAR2KCNH2CYP1A2CYP3A4 | |
| SCHEMBL2645004 | 0.87 | GCK (0.98) | GCKFFAR2KCNH2 | |
| SCHEMBL2646496 | 0.87 | GCK (0.83) | GCKFFAR2KCNH2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1245394-C | Substituted phenylacetamides and their use as glucokinase activators | HOFFMANN LA ROCHE (CH) | 2006-03-15 | — | — | CN | claimed |
| EP-1282611-B1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2004-10-20 | — | — | EP | claimed |
| CN-1427829-A | Substituted phenylacetamides and their use as glucokinase activators | HOFFMANN LA ROCHE (CH) | 2003-07-02 | — | — | CN | claimed |
| EP-1282611-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-12 | — | — | EP | claimed |
| US-6384220-B2 | ANTIDIABETIC AGENTS INCREASING THE EXPRESSION OF GLUCOKINASE (GK) TO IMPROVE GLUCOSE TOLERANCE; INCREASE IN GLUCOSE EXPOSURE COUPLED THROUGH GK IN BETA-CELLS TO INCREASE INSULIN SECRETION AND IN HEPATOCYTES TO INCREASE GLYCOGEN DEPOSITION | HOFFMANN-LA ROCHE INC. | 2002-05-07 | — | — | US | claimed |
| US-20020002190-A1 | Para-aryl or heterocyclic substituted phenyl glucokinase activators | HOFFMANN-LA ROCHE INC. | 2002-01-03 | — | — | US | claimed |
| WO-2001085706-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-15 | — | — | WO | claimed |
| CN-1245394-C | Substituted phenylacetamides and their use as glucokinase activators | HOFFMANN LA ROCHE (CH) | 2006-03-15 | — | — | CN | disclosed |
| EP-1282611-B1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2004-10-20 | — | — | EP | disclosed |
| CN-1427829-A | Substituted phenylacetamides and their use as glucokinase activators | HOFFMANN LA ROCHE (CH) | 2003-07-02 | — | — | CN | disclosed |
| EP-1282611-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-12 | — | — | EP | disclosed |
| US-6384220-B2 | ANTIDIABETIC AGENTS INCREASING THE EXPRESSION OF GLUCOKINASE (GK) TO IMPROVE GLUCOSE TOLERANCE; INCREASE IN GLUCOSE EXPOSURE COUPLED THROUGH GK IN BETA-CELLS TO INCREASE INSULIN SECRETION AND IN HEPATOCYTES TO INCREASE GLYCOGEN DEPOSITION | HOFFMANN-LA ROCHE INC. | 2002-05-07 | — | — | US | disclosed |
| US-20020002190-A1 | Para-aryl or heterocyclic substituted phenyl glucokinase activators | HOFFMANN-LA ROCHE INC. | 2002-01-03 | — | — | US | disclosed |
| WO-2001085706-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002190-A1 | Para-aryl or heterocyclic substituted phenyl glucokinase activators | GCKR, GCK, PDXK | GCK 2/4885FFAR2 940/4885KCNH2 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.